McGlone Suttner Wealth Management Inc. lifted its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 74.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 9,871 shares of the company's stock after purchasing an additional 4,218 shares during the quarter. McGlone Suttner Wealth Management Inc.'s holdings in Johnson & Johnson were worth $1,637,000 at the end of the most recent quarter.
A number of other large investors have also recently made changes to their positions in the company. Lantz Financial LLC boosted its holdings in shares of Johnson & Johnson by 3.3% during the first quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. purchased a new stake in shares of Johnson & Johnson during the fourth quarter worth about $453,000. State of Wyoming grew its stake in Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after purchasing an additional 10,279 shares in the last quarter. Joel Isaacson & Co. LLC grew its stake in Johnson & Johnson by 3.5% in the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock worth $12,294,000 after purchasing an additional 2,526 shares in the last quarter. Finally, Range Financial Group LLC grew its stake in Johnson & Johnson by 18.9% in the first quarter. Range Financial Group LLC now owns 15,886 shares of the company's stock worth $2,635,000 after purchasing an additional 2,529 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.
Johnson & Johnson Stock Performance
Shares of NYSE:JNJ traded down $0.16 during mid-day trading on Wednesday, reaching $155.63. The company had a trading volume of 588,858 shares, compared to its average volume of 8,027,974. The company has a current ratio of 1.26, a quick ratio of 1.03 and a debt-to-equity ratio of 0.49. The firm has a market cap of $374.46 billion, a price-to-earnings ratio of 17.33, a PEG ratio of 2.35 and a beta of 0.41. The company's 50-day moving average price is $153.67 and its 200-day moving average price is $154.25. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.
Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The firm had revenue of $21.89 billion for the quarter, compared to analysts' expectations of $21.65 billion. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio is currently 57.84%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on JNJ shares. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price target for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. The Goldman Sachs Group raised Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Raymond James Financial cut their target price on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a research note on Monday, April 14th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Finally, Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $181.00 price target on shares of Johnson & Johnson in a research note on Thursday, June 5th. Eleven analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $170.88.
View Our Latest Stock Analysis on JNJ
Johnson & Johnson Profile
(
Free Report)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Further Reading
Before you consider Johnson & Johnson, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.
While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
